EUCTR2015-001755-72-DE进行中（未招募）1 期
Investigating Denosumab as an add-on to neoadjuvant chemotherapy in RANK/L-positive or RANK/L-negative primary breast cancer and two different nab-Paclitaxel schedules in a 2x2 factorial design (GeparX) - GeparX
German Breast Group0 个研究点目标入组 778 人开始时间: 2016年9月9日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 778
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Written informed consent according to local regulatory requirements prior to beginning specific protocol procedures.
- •Complete baseline documentation must be submitted via MedCODES to GBG Forschungs GmbH.
- •Unilateral or bilateral primary carcinoma of the breast, confirmed histologically by core biopsy. Fine-needle aspiration from the breast lesion alone is not sufficient. Incisional biopsy or axillary clearance is not allowed. In case of bilateral cancer, the investigator has to decide prospectively which side will be evaluated for the primary endpoint.
- •Tumor lesion in the breast with a palpable size of ? 2 cm or a sonographical size of ? 1 cm in maximum diameter. The lesion has to be measurable in two dimensions, preferably by sonography. In case tumor isn’t measurable by sonography, then MRI or mammography is sufficient. In case of inflammatory disease, the extent of inflammation can be used as measurable lesion.
- •Patients must be in the following stages of disease:
- •- cT2 - cT4a-d or
- •- cT1c and cN+ or
- •- cT1c and pNSLN+ or
- •- cT1c and ER-neg and PR-neg or
- •- cT1c and Ki67>20% or
- •- cT1c and HER2-pos
- •Patients must have stage cT1c - cT4a-d disease.
- •In patients with multifocal or multicentric breast cancer, the largest lesion should be measured.
- •Centrally confirmed ER-negative, and PR-negative and HER2-status. Central pathology includes also assessment of HER2, Ki-67, TIL and RANK/L status on core biopsy. ER/PR negative is defined as <=1% stained cells and HER2-positive is defined as IHC 3+ or in-situ hybridization (ISH) and according to ASCO-CAP guidelines as of 2013. LPBC (lymphocyte predominant breast cancer) is defined as more than 50% stromal tumour infiltrating lymphocytes. Formalin-fixed, paraffin-embedded (FFPE) breast tissue from core biopsy has therefore to be sent to the GBG central pathology laboratory prior to randomization.
- •Age ? 18 years.
- •Karnofsky Performance status index ? 90%.
- •Confirmed normal cardiac function by ECG and cardiac ultrasound (LVEF or shortening fraction) within 3 months prior to randomization. Results must be above the normal limit of the institution. For patients with HER2-positive tumors LVEF must be above 55%.
- •Laboratory requirements:
- •- Absolute neutrophil count (ANC) ? 2.0 x 109 / L and
- •- Platelets ? 100 x 109 / L and
- •- Hemoglobin ? 10 g/dL (? 6.2 mmol/L)
- •Hepatic function
- •- Total bilirubin ? 1.5x UNL and
- •- ASAT (SGOT) and ALAT (SGPT) ? 1.5x UNL and
- •- Alkaline phosphatase ? 2.5x UNL.
- •Serum calcium or albumin-adjusted serum calcium =2.0 mmol/L (8.0 mg/dL) and =2.9 mmol/L (11.5 mg/dL). Hypocalcemia has to be corrected before study entry by supplementation of calcium and vitamin D.
- •Negative serum pregnancy test within 14 days prior to randomization for all women of childbearing potential with the result available before dosing.
- •Complete staging work-up within 3 months prior to randomization. All patients must have bilateral mammography, breast ultrasound (? 21 days), breast MRI (optional). Chest X-ray (PA and lateral), abdominal ultrasound or CT scan or MRI, and bone scan in case of high risk for primary metastasis. In case of a positive bone scan, bone X-ray or CT scan is mandatory. Other tests may be performed as clinically indicated.
- •Patients must agree with central pathology testing of core biopsy specimen and final pathology specimen and be available and compliant for treatment and follow-up.
- •Are the trial subjects under
排除标准
- •Pure lobular carcinomas (lobular histology and G1/G2 and HR+/HER2-)
- •Patients with stages cT1a, cT1b, or any M1.
- •Prior chemotherapy for any malignancy.
- •Prior radiation therapy for breast cancer.
- •History of disease with influence on bone metabolism, such as osteoporosis, Paget’s disease of bone, primary hyperparathyroidism requiring treatment at the time of randomization or considered likely to become necessary within the subsequent six months.
- •Use of bisphosphonates or denosumab within the past 1 year.
- •Significant dental/oral disease, including prior history or current evidence of osteonecrosis/ osteomyelitis of the jaw, active dental or jaw condition which requires oral surgery, non-healed dental/oral surgery, planned invasive dental procedure for the course of the study.
- •Last visit at dentist > 1½ year ago.
- •Pregnant or lactating patients. Patients of childbearing potential must agree to use one highly effective or two effective forms of non-hormonal contraceptive measures during study treatment and 7 months following the last dose of mAbs.
- •Inadequate general condition (not fit for anthracycline-taxane-targeted agents-based chemotherapy).
- •Previous malignant disease being disease-free for less than 5 years (except CIS of the cervix and non-melanomatous skin cancer).
- •Known or suspected congestive heart failure (>NYHA I) and / or coronary heart disease, angina pectoris requiring antianginal medication, previous history of myocardial infarction, evidence of transmural infarction on ECG, uncontrolled or poorly controlled arterial hypertension (i.e. BP >140 / 90 mm Hg under treatment with two antihypertensive drugs), rhythm abnormalities requiring permanent treatment, clinically significant valvular heart disease.
- •History of significant neurological or psychiatric disorders including psychotic disorders, dementia or seizures that would prohibit the understanding and giving of informed consent.
- •Pre-existing motor or sensory neuropathy of a severity ? grade 2 by NCI-CTC criteria v 4.0.
- •Currently active infection.
- •Incomplete wound healing.
- •Definite contraindications for the use of corticosteroids.
- •Known hypersensitivity reaction to one of the compounds or incorporated substances used in this protocol inclusive calcium and vitamin D. Known hereditary fructose intolerance.
- •Concurrent treatment with:
- •-chronic corticosteroids unless initiated > 6 months prior to study entry and at low dose (10 mg or less methylprednisolone or equivalent).
- •-sex hormones. Prior treatment must be stopped before study entry.
- •-other experimental drugs or any other anti-cancer therapy.
- •Participation in another clinical trial with any investigational, not marketed drug within 30 days prior to study entry.
研究者
相似试验
已完成
不适用
The prospective study of denosumab for the treatment of osteoporosis in hemodialysis patientsOsteoporosisJPRN-UMIN000022179Yujinkai Medical Corporation Yujin-yamazaki Hospital38
进行中（未招募）
1 期
A Study to Evaluate Denosumab in the Treatment of Postmenopausal Osteoporosis. FREEDOM (Fracture REduction Evaluation of Denosumab in Osteoporosis every 6 Months)Treatment of postmenopausal osteoporosisMedDRA version: 8.1 Level: LLT Classification code 10031285 Term: Osteoporosis postmenopausalEUCTR2004-000138-35-GBAmgen Inc7,869
已完成
不适用
The efficacy of re-challenge of denosumab in postmenopausal women with hormone receptor-positive breast cancer who are currently on or will iniate an aromatase inhibitor in the adjuvant settingbreast cancerJPRN-UMIN000030328Kyoto Prefectural University of medicine10
进行中（未招募）
1 期
Effects of the inhibition of RANKL in pre-menopausal early breast cancer patientsWe have designed this study to investigate if denosumab can modulate a number of biological processes including prolferation, RANK signaling and the mammary stem cell subpopulation.MedDRA version: 19.0Level: LLTClassification code 10006190Term: Breast cancer invasive NOSSystem Organ Class: 100000004864EUCTR2011-006224-21-BEJules Bordet Institute39
招募中
不适用
Comparison of therapeutic effects of denosumab and romosozumab using Propensity Score Matching in postmenopausal osteoporosis patientsPrimary osteoprosisosteoprosisD0 1 0 0 2 4JPRN-jRCT1041200090Kobayakawa Tomonori150